911040-40-9

Basic information

• Product Name: (R)-N-methoxy-3-(4-methoxybenzyl)-N-methyl-2-oxothiazolidine-4-carboxamide
• Synonyms: (R)-N-methoxy-3-(4-methoxybenzyl)-N-methyl-2-oxothiazolidine-4-carboxamide
• CAS NO: 911040-40-9
• Molecular Weight: 310.374
• Mol File: 911040-40-9.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: (R)-N-methoxy-3-(4-methoxybenzyl)-N-methyl-2-oxothiazolidine-4-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-N-methoxy-3-(4-methoxybenzyl)-N-methyl-2-oxothiazolidine-4-carboxamide(911040-40-9)
• EPA Substance Registry System: (R)-N-methoxy-3-(4-methoxybenzyl)-N-methyl-2-oxothiazolidine-4-carboxamide(911040-40-9)

Safety Data

• Hazardous Substances Data: 911040-40-9(Hazardous Substances Data)

Upstream product

• 101860-50-8 (-)-3-(4-methoxybenzyl)-2-oxo-thiazolidine-4-carboxylic acid ethyl ester 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 139944-38-0 (-)-3-(4-methoxybenzyl)-2-oxo-thiazolidine-4-carboxylic acid 
• 1117-97-1 N,0-dimethylhydroxylamine 

Downstream Products

• 101860-51-9 (-)-4-acetyl-3-(4-methoxybenzyl)-thiazolidinon-2-one 

Relevant articles and documents

Structure-Activity Studies of Truncated Latrunculin Analogues with Antimalarial Activity

Malarial parasites employ actin dynamics for motility, and any disruption to these dynamics renders the parasites unable to effectively establish infection. Therefore, actin presents a potential target for malarial drug discovery, and naturally occurring actin inhibitors such as latrunculins are a promising starting point. However, the limited availability of the natural product and the laborious route for synthesis of latrunculins have hindered their potential development as drug candidates. In this regard, we recently described novel truncated latrunculins, with superior actin binding potency and selectivity towards P. falciparum actin than the canonical latrunculin B. In this paper, we further explore the truncated latrunculin core to summarize the SAR for inhibition of malaria motility. This study helps further understand the binding pattern of these analogues in order to develop them as drug candidates for malaria.

Divergent approach to building a latrunculin family derived hybrid macrocyclic toolbox

A divergent approach to obtain a latrunculin family based hybrid macrocyclic toolbox is developed. A practical, stereoselective synthesis of a common substructure present in latrunculin A and latrunculol A was achieved. This was further utilized in the ma

Cytoskeletal active compounds, compositions and use

The present invention is directed to synthetic cytoskeletal active compounds that are related to natural Latrunculin A or Latrunculin B. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically